Harrow Health Inc
Change company Symbol lookup
Select an option...
HROW Harrow Health Inc
SLAB Silicon Laboratories Inc
NCLH Norwegian Cruise Line Holdings Ltd
SNMSF Spin Master Corp
IFBD Infobird Co Ltd
JACK Jack in the Box Inc
MVLY Mission Valley Bancorp
CLSD Clearside Biomedical Inc
GBRGU Goldenbridge Acquisition Ltd
CHMI-B Cherry Hill Mortgage Investment Corp
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Harrow Health, Inc. is an ophthalmic-focused healthcare company. The Company's business specializes in the development, production and sale of medications that serve unmet needs in the marketplace through its subsidiaries and deconsolidated companies. The Company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, Inc. (Visionology), a direct-to-consumer eye care subsidiary focused on chronic eye disease. In addition, the Company holds non-controlling equity positions in Surface Ophthalmics, Inc. (Surface) and Melt Pharmaceuticals, Inc. (Melt). It also owns royalty rights in various drug candidates being developed by Surface and Melt.

Closing Price
$7.99
Day's Change
-0.13 (-1.60%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.17
Day's Low
7.83
Volume
(Light)
Volume:
33,144

10-day average volume:
66,743
33,144

Company Profile

Harrow Health, Inc. is an ophthalmic-focused healthcare company. The Company's business specializes in the development, production and sale of medications that serve unmet needs in the marketplace through its subsidiaries and deconsolidated companies. The Company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, Inc. (Visionology), a direct-to-consumer eye care subsidiary focused on chronic eye disease. In addition, the Company holds non-controlling equity positions in Surface Ophthalmics, Inc. (Surface) and Melt Pharmaceuticals, Inc. (Melt). It also owns royalty rights in various drug candidates being developed by Surface and Melt.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
2.56x
Price/Book (MRQ)
37.62x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

August 2022
Current Month
555.5K
Previous Month
521.9K
Percent of Float
2.23%
Days to Cover
5.1881 Days

Share Information

HROW is in a share class of common stock
Float
24.9M
Shares Outstanding
27.1M
Institutions Holding Shares
103
60.16%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Mark L. BaumChmn.
  • Andrew R. BollCFO
  • John P. SaharekCorp.Exec.
  • Richard L. LindstromDir.
  • Martin A. Makary

Address

Insider Trading

During the most recent quarter, 41K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.